Abstract: The present invention relates to pharmaceutical comprising multimeric-multiepitope influenza polypeptides, to processes for their production and to their use as immunizing subjects against influenza. In particular, the invention relates to stable aqueous microparticulate suspensions and solid compositions comprising a multimeric multiepitope polypeptide.
Type:
Application
Filed:
August 27, 2019
Publication date:
January 2, 2020
Applicant:
BIONDVAX PHARMACEUTICALS LTD.
Inventors:
Ram URITSKI, Barry COHEN, Zohar GADRI, Shimon HASSIN
Abstract: Pharmaceutical suspensions of multimeric-multiepitope influenza polypeptides, processes for their production and their use as immunizing subjects against influenza. In particular, stable aqueous microparticulate suspensions of a multimeric multiepitope polypeptide are disclosed.
Type:
Grant
Filed:
April 1, 2015
Date of Patent:
October 1, 2019
Assignee:
BIONDVAX PHARMACEUTICALS LTD.
Inventors:
Ram Uritski, Barry Cohen, Zohar Gadri, Shimon Hassin
Abstract: An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X1ZX2Z . . . Xm)nB or B(X1)nZ(X2)nZ . . . (Xm)nB; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X1, X2 . . . Xm is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.
Abstract: The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.
Abstract: An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X1ZX2Z . . . Xm)nB or B(X1)nZ(X2)nZ . . . (Xm)nB; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X1, X2 . . . Xm is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.
Abstract: The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.
Abstract: The present invention relates to multimeric multi-epitope peptide-based vaccines. In particular, the present invention relates to the use of multimeric multi-epitope peptide-based vaccines eliciting protective immunity to influenza.